Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration

New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasniqi, Eriseld, Goeman, Frauke, Pulito, Claudio, Palcau, Alina Catalina, Ciuffreda, Ludovica, Di Lisa, Francesca Sofia, Filomeno, Lorena, Barba, Maddalena, Pizzuti, Laura, Cappuzzo, Federico, Sanguineti, Giuseppe, Maugeri-Saccà, Marcello, Ciliberto, Gennaro, Fanciulli, Maurizio, Blandino, Giovanni, Vici, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739115/
https://www.ncbi.nlm.nih.gov/pubmed/36498861
http://dx.doi.org/10.3390/ijms232314534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739115/
https://www.ncbi.nlm.nih.gov/pubmed/36498861
http://dx.doi.org/10.3390/ijms232314534

Ejemplares similares